Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 11, 2007, Pages 4118-4124

  Quenelle, Debra C ^a,d   Prichard, Mark N ^a   Keith, Kathy A ^a   Hruby, Dennis E ^b   Jordan, Robert ^b   Painter, George R ^c   Robertson, Alice ^c   Kern, Earl R ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b SIGA Technologies Incorporated   (United States)

^c Chimerix Inc   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 TRIFLUOROMETHYL N [3,3A,4,4A,5,5A,6,6A OCTAHYDRO 1,3 DIOXO 4,6 ETHENOCYCLOPROP[F]ISOINDOL 2(1H) YL]BENZAMIDE; CIDOFOVIR; CMX 001; HEXADECYLOXYPROPYLCIDOFOVIR; ST 246; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COWPOX VIRUS; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LETHALITY; MORTALITY; MOUSE; NONHUMAN; ORTHOPOXVIRUS; PRIORITY JOURNAL; SURVIVAL; TREATMENT RESPONSE; VACCINIA VIRUS; VIRUS INFECTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BENZAMIDES; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COWPOX VIRUS; CYTOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOINDOLES; MALE; MICE; MICE, INBRED BALB C; ORTHOPOXVIRUS; PHOSPHONIC ACIDS; POXVIRIDAE INFECTIONS; TREATMENT OUTCOME; VACCINIA VIRUS; VERO CELLS; VIRUS REPLICATION;

EID: 35848968505     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00762-07     Document Type: Article

References (30)

1. Andrei, G., D. B. Gammon, P. Fiten, E. De Clercq, G. Oppendakker, R. Snoeck, and D. H. Evans. 2006. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J. Virol. 80:9391-9401.
2. Reference deleted.
3. Bray, M., M. Martinez, D. F. Smee, D. Kefauver, E. Thompson, and J. W. Huggins. 2000. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181:10-19.
4. Buller, R. M., G. Owens, J. Schriewer, L. Melman, J. R. Beadle, and K. Y. Hostetler. 2004. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318:474-481.
5. Ciesla, S. L., J. Trahan, W. B. Wan, J. R. Beadle, K. A. Aldern, G. R. Painter, and K. Y. Hostetler. 2003. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes accumulation in the kidney. Antivir. Res. 59:163-171.
6. Fedele, C. G., A. Negredo, F. Molero, M. P. Sanchez-Seco, and A. Tenorio. 2006. Use of internally controlled real-time PCR for detection of variola virus and other orthopoxviruses infecting humans. J. Clin. Microbiol. 44:4464-4470.
7. Finkel, E. 2001. Engineered mouse virus spurs bioweapon fears. Science 291:585.
8. Reference deleted.
9. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
10. Jackson, R. J., A. J. Ramsay, C. D. Christensen, S. Beaton, D. F. Hall, and I. A. Ramshaw. 2001. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J. Virol. 75:1205-1210.
11. Keith, K. A., M. J. Hitchcock, W. A. Lee, A. Holý, and E. R. Kern. 2003. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob. Agents Chemother. 47:2193-2198.
12. Kern, E. R. 2003. In vitro activity of potential anti-poxviral agents. Antivir. Res. 57:35-40.
13. Reference deleted.
14. Kornbluth, R. S., D. F. Smee, R. W. Sidwell, V. Snarsky, D. H. Evans, and K. Y. Hostetler. 2006. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob. Agents Chemother. 50:4038-4043.
15. Lacy, S. A., M. J. Hitchcock, W. A. Lee, P. Tellier, and K. C. Cundy. 1998. Effect of oral probenicid on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol. Sci. 44:97-106.
16. Müllbacher, A., and M. Lobigs. 2001. Creation of killer poxvirus could have been predicted. J. Virol. 75:8353-8355.
17. Painter, G. R., and K. Y. Hostetler. 2004. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol. 8:423-427.
18. Prichard, M. N., K. A. Keith, D. C. Quenelle, and E. R. Kern. 2006. Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections. Antimicrob. Agents Chemother. 50:1336-1341.
19. Prichard, M. N., and C. Shipman, Jr. 1990. A three dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-205.
20. Quenelle, D. C., R. M. Buller, S. Parker, K. A. Keith, D. E. Hruby, R. Jordan, and E. R. Kern. 2007. Efficacy of delayed treatment with ST-246 given orally against systemic orthopox infections in mice. Antimicrob. Agents Chemother. 51:689-695.
21. ProMED-mail. 2007. Smallpox vaccine, eczema vaccination - USA. Archive no. 20070318.0947. http://www.promedmail.org/.
22. Quenelle, D. C., D. J. Collins, and E. R. Kern. 2003. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox infections in mice. Antimicrob. Agents Chemother. 47:3275-3280.
23. Quenelle, D. C., D. J. Collins, W. B. Wan, J. R. Beadle, K. Y. Hostetler, and E. R. Kern. 2004. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48:404-412.
24. Quenelle, D. C., K. A. Keith, and E. R. Kern. 2006. In vitro and in vivo evaluation of isatin-beta-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. Antivir. Res. 71:24-30.
25. Robbins, S. J., R. J. Jackson, F. Fenner, S. Beaton, J. Medveczky, I. A. Ramshaw, and A. J. Ramsay. 2005. The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4. Antivir. Res. 66:1-7.
26. Skottman, T., H. Piiperinan, H. Hyytiäinen, V. Myllys, M. Skurnik, and S. Nikkari. 2007. Simultaneous real-time PCR detection of Bacillus anthracis, Francisella tularensis and Yersinia pestis. Eur. J. Clin. Microbiol. Infect. Dis. 26:207-211.
27. Smee, D. F., K. W. Bailey, and R. W. Sidwell. 2003. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice. Chemotherapy 49:126-131.
28. Smee, D. F., M. K. Wandersee, K. W. Bailey, K. Y. Hostetler, A. Holy, and R. W. Sidwell. 2005. Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice. Antivir. Chem. Chemother. 16:203-211.
29. Smee, D. F., M. Wong, K. W. Bailey, J. R. Beadle, K. Y. Hostetler, and R. W. Sidwell. 2004. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int. J. Antimicrob. Agents 23:430-437.
30. Yang, G., D. C. Pevear, M. H. Davies, M. S. Collett, T. Bailey, S. Rippen, L. Barone, C. Burns, G. Rhodes, S. Tohan, J. W. Huggins, R. O. Baker, R. L. M. Buller, E. Touchette, K. Waller, J. Schriewer, J. Neyts, E. DeClercq, K. Jones, D. Hruby, and R. Jordan. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:13139-13149.